Dragonfly Therapeutics Initiates Phase 1/2 Study of DF1001 in Patients with Advanced Solid Tumors
Dragonfly Therapeutics, a biotechnology company developing novel immunotherapies that harness the innate immune system to treat disease, announced that the first patient was dosed in a Phase 1/2 study of DF1001 at The University of Texas MD Anderson Cancer Center
SurgiMab – Phase 3 Trial Evaluating a Novel Fluorescent Tumor-specific Antibody for the Improvement of Surgical Outcomes in Colorectal Cancer Patients
SurgiMab, a late-stage biotechnology company pioneering a new antibody-based fluorescence-guided approach with the aim to improve cancer surgery and clinical outcomes for patients, announces that the first US patient has been recruited into its on-going pivotal Phase 3 clinical trial
Abalos Therapeutics Launches with €12M Series A
Abalos Therapeutics launches with €12M in Series A funding to get the development of its arenavirus-based cancer therapies off the ground. Boehringer Ingelheim Venture Fund and Gründerfonds Ruhr co-led the investment round, with additional contributions from NRW.BANK and High-Tech Gründerfonds. Abalos, which
Tacalyx Raises €7 Million in Seed Funding to Generate First in Class Anti-TACA Antibodies for Cancer Treatment
Tacalyx, a biotech company focused on the discovery and development of novel anti-TACA (Tumor Associated Carbohydrate Antigens) cancer therapies, announced that it has successfully secured €7 million in seed funding. The funding round involves a syndicate of leading European life
Varian buys software developer for AI cancer work
Varian said it is investing in privately held Oncora Medical and will partner with the software company to develop machine learning-guided decision support tools. The aim is to help doctors create personalized treatment plans for cancer patients. Financial terms weren't
Prescient gets FDA breakthrough status for colorectal cancer test
Prescient Metabiomics has received FDA breakthrough status for its non-invasive colorectal cancer test. The test, called LifeKit Prevent, identifies microbial DNA and RNA biomarkers associated with the new, abnormal growth of tissue in the gastrointestinal tract. By detecting these changes